Corporate Earnings

Total revenues rose $232.5 million from $120.7 million to $353.2 million, roughly 2.9 times the prior year level on a calculated basis. Net product revenue increased $145.3 million to $253.3 million, which management linked to continued commercial expansion fueled by patient demand.

Revenue grew $38.7 million, or 5%, to $841.5 million. CEO Stephen Kramer credited the quarter's strength to a diversified portfolio, including 13% growth in back-up care. Lower revenue from full service centers closed over the past twelve months partly offset that growth.

The company submitted itsQuarterly Reportfor the period ended September 30, 2026 on October 29, 2026. Post-transplant tests together with NavDx accounted for 86% of revenue in the quarter, up from 72% a year earlier, and testing volume reached about 75,900, a 51% rise.

Net sales were $129.3 million, an increase of $1.6 million, or 1.2%, from $127.8 million in the prior year quarter. The company credited the gain mainly to higher consumerDemandwhile keeping its focus on optimizingAdvertisingspend.

Key HighlightsAdvanced Micro Devices (NASDAQ:AMD) reports third quarter 2026 results after the close on Tuesday, November 3, 2026. Calendar consensus shows adjusted EPS of USD 1.94, and theMarket Valuesits near USD 838.05 billion.Management guided third quarterRevenueto roughly USD 13 billion, give or take USD …

Key HighlightsAmgen (NASDAQ:AMGN) reports third quarter 2026 results after the close on Tuesday, November 3, 2026, against calendar consensus adjusted EPS of USD 5.79. TheMarket Valueis near USD 254.44 billion.Second quarterRevenuereached USD 10.1 billion, a 10 percent gain, and non-GAAP EPS was USD 6.29. …

Key HighlightsArista Networks (NYSE:ANET) is due to report third quarter 2026 results after the close on Tuesday, November 3, 2026, with calendar consensus EPS of USD 1.08 and aMarket Valueof about USD 216 billion, shown as USD 215.8 billion.Second quarterRevenuewas USD 3.036 billion, up …